0317 GMT - Cochlear shakes off its bear at Macquarie but remains less attractive to the investment bank's analysts than other Australia-listed medical-technology stocks. Shares in the hearing-implant manufacturer have fallen by about 16% since August. This leaves the stock at a level implying market-share gains and profit margins in line with Macquarie analysts' expectations. However, they point out that it is trading at about 42 times EPS on a 12-month forward basis, compared with about 27 for vaccine maker CSL and 25 for breath-tech provider ResMed. Both those companies are forecast to grow fiscal 2025 EPS at a faster rate, they add. Macquarie raises its target price by 2.1% to A$289.00 and upgrades its recommendation to neutral from underperform. Shares are up 0.35% at A$284.24. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
October 31, 2024 23:17 ET (03:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。